Evaluating the HER-2 status of breast cancer using mammography radiomics features

被引:39
|
作者
Zhou, Jing [1 ,2 ,4 ]
Tan, Hongna [1 ,2 ]
Bai, Yan [1 ,2 ]
Li, Jie [3 ]
Lu, Qing [1 ,2 ]
Chen, Rushi [1 ,2 ]
Zhang, Menghuan [1 ,2 ]
Feng, Qin [1 ,2 ]
Wang, Meiyun [1 ,2 ]
机构
[1] Henan Prov Peoples Hosp, Dept Radiol, 7 Rd,Weiwu Rd, Zhengzhou 450003, Henan, Peoples R China
[2] Imaging Diag Neurol Dis & Res Lab Henan Prov, Zhengzhou, Henan, Peoples R China
[3] Huiying Med Technol Inc, Beijing, Peoples R China
[4] Mudanjiang Med Univ, Med Imaging Sch, Mudanjiang 157011, Heilongjiang, Peoples R China
基金
中国国家自然科学基金;
关键词
Breast cancer; HER-2; Radiomics; Mammography; THERAPY;
D O I
10.1016/j.ejrad.2019.108718
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: The aim of our study was to evaluate the HER-2 status in breast cancer patients using mammography (MG) radiomics features. Methods: A total of 306 Chinese female patients with invasive ductal carcinoma of no special type (IDC-NST) enrolled from January 2013 to July 2018 were divided into a training set (n= 244) and a testing set (n= 62). One hundred and eighty-six radiomics features were extracted from digital MG images based on the training set. The least absolute shrinkage and selection operator (LASSO) method was used to select the optimal predictive features for HER-2 status from the training set. Both support vector machine (SVM) and logistic regression models were employed based on the selected features. The area under the receiver operating characteristic (ROC) curves (AUCs) of the training set and testing set were used to evaluate the predictive performance of the models. Results: Compared with the SVM model, the performance of the logistic regression model using a combination of cranial caudal (CC) and mediolateral oblique (MLO) MG views was optimal. In the training set, the sensitivity, specificity, accuracy and area under the curve (AUC) values of the logistic regression model for evaluating HER-2 status based on quantitative radiomics features were 87.29%, 58.73%, 80.00% and 0.846 (95% confidence interval (CI), 0.800-0.887), respectively, and in the testing set, the values were 73.91%, 68.75%, 77.00% and 0.787 (95% CI, 0.673-0.885), respectively. Conclusions: Radiomics features could be an efficient tool for the preoperative evaluation of HER-2 status in patients with breast cancer.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] HER-2 ultra-low breast cancer: exploring the clinicopathological features and prognosis in a retrospective study
    Shi, Jiajie
    Zhang, Liqiu
    Geng, Cuizhi
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [42] HER-2/neu analysis in breast cancer bone metastases
    Zustin, J.
    Boddin, K.
    Tsourlakis, M. C.
    Burandt, E.
    Mirlacher, M.
    Jaenicke, F.
    Izbicki, J.
    Ruether, W.
    Rueger, J. M.
    Bokemeyer, C.
    Simon, R.
    Sauter, G.
    JOURNAL OF CLINICAL PATHOLOGY, 2009, 62 (06) : 542 - 546
  • [43] HER-2/neu expression in primary and metastatic breast cancer
    Lower, Elyse E.
    Glass, Eleanor
    Blau, Robbin
    Harman, Stacy
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 113 (02) : 301 - 306
  • [44] HER-2: genetic polymorphism and breast cancer
    Milano, G.
    ONCOLOGIE, 2008, 10 (01) : 37 - 39
  • [45] Bilateral Synchronous Breast Cancer and HER-2/neu Overexpression
    Malek Safa
    Elyse E. Lower
    P.O. Hasselgren
    Eric S. Hungness
    Paula Gazder
    Bernard Aron
    Elizabeth A. Shaughnessy
    Rawia Yassin
    Breast Cancer Research and Treatment, 2002, 72 : 195 - 201
  • [46] HER-2 Signaling and Inhibition in Breast Cancer
    Browne, B. C.
    O'Brien, N.
    Duffy, M. J.
    Crown, J.
    O'Donovan, N.
    CURRENT CANCER DRUG TARGETS, 2009, 9 (03) : 419 - 438
  • [47] Multiparametric MRI-based radiomic nomogram for predicting HER-2 2+status of breast cancer
    Wang, Haili
    Sang, Li
    Xu, Jingxu
    Huang, Chencui
    Huang, Zhaoqin
    HELIYON, 2024, 10 (09)
  • [48] Correlation Between HER-2 Gene Amplification or Protein Expression and Clinical Pathological Features of Breast Cancer
    Shi, Pengfei
    Chen, Cheng
    Yao, Yufeng
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2019, 34 (01) : 42 - 46
  • [49] Comparison of in situ hybridization methods for the assessment of HER-2/neu gene amplification status in breast cancer using a tissue microarray
    Malicka-Durczak, Anna
    Korski, Konstanty
    Ibbs, Matthew
    REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2012, 17 (01) : 44 - 49
  • [50] Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature
    Arslan, Cagatay
    Sari, Ebru
    Aksoy, Sercan
    Altundag, Kadri
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2011, 15 (01) : 21 - 30